Molecular pathology of myeloproliferative neoplasms

American Journal of Clinical Pathology

Volumn 133, Issue 4, 2010, Pages 602-615

  Klco, Jeffery M ^a   Vij, Ravi ^a   Kreisel, Friederike H ^a   Hassan, Anjum ^a   Frater, John L ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Chronic eosinophilic leukemia; Chronic myelogenous leukemia; Chronic neutrophilic leukemia; Essential thrombocythemia; Mastocytosis; Molecular pathology; Myeloproliferative neoplasm; Myeloproliferative neoplasms; Polycythemia vera; Primary myelofibrosis; Unclassifiable

Indexed keywords

CYTARABINE; IMATINIB; INTERFERON; JANUS KINASE 2; STAT PROTEIN;

CHRONIC MYELOID LEUKEMIA; CHRONIC NEUTROPHILIC LEUKEMIA; CLINICAL FEATURE; DISEASE CLASSIFICATION; EOSINOPHILIA; EOSINOPHILIC LEUKEMIA; HISTOPATHOLOGY; HUMAN; MASTOCYTOSIS; MYELOID METAPLASIA; MYELOPROLIFERATIVE DISORDER; MYELOPROLIFERATIVE NEOPLASM; PHILADELPHIA 1 CHROMOSOME; POLYCYTHEMIA VERA; PRIORITY JOURNAL; REVIEW; THROMBOTIC THROMBOCYTOPENIC PURPURA; TREATMENT RESPONSE; WORLD HEALTH ORGANIZATION; CLASSIFICATION; DIFFERENTIAL DIAGNOSIS; GENETICS; MYELOID PROGENITOR CELL; PATHOLOGY; SIGNAL TRANSDUCTION;

DIAGNOSIS, DIFFERENTIAL; HUMANS; JANUS KINASE 2; MYELOID PROGENITOR CELLS; MYELOPROLIFERATIVE DISORDERS; SIGNAL TRANSDUCTION;

EID: 77950476613     PISSN: 00029173     EISSN: None     Source Type: Journal    
DOI: 10.1309/AJCPPPZ1WFVGNE4A     Document Type: Review

References (144)

1. Jaffe ES, Harris NL, Stein H, et al, eds. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC Press; 2001. World Health Organization Classification of Tumours.
2. Swerdlow SH, Campo E, Harris NL, et al, eds. WHO Classification of Tumours of the Haematopoietic and Lymphoid Tissues. Lyon, France: IARC Press; 2008.
3. Tefferi A, Vardiman JW. Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms. Leukemia. 2008;22:14-22.
4. Bennett J. Two cases of disease and enlargement of the spleen in which death took place from the presence of purulent matter in the blood. Edinburgh Med Surg J. 1845;64:413-423.
5. Virchow R. Weisses Blut. Froiep's Notizen. 1845;36:151-156.
6. Cortes JE, Talpaz M, Kantarjian H. Chronic myelogenous leukemia: a review. Am J Med. 1996;100:555-570.
7. Goldman JM. Chronic myeloid leukemia. Curr Opin Hematol. 1997;4:277-285.
8. Spiers AS, Bain BJ, Turner JE. The peripheral blood in chronic granulocytic leukaemia: study of 50 untreated Philadelphia-positive cases. Scand J Haematol. 1977;18:25-38.
9. Spiers AS. Metamorphosis of chronic granulocytic leukaemia: diagnosis, classification, and management. Br J Haematol. 1979;41:1-7.
10. Klco JM, Kreisel FH, Zehnbauer BA, et al. The spectrum of adult B-lymphoid leukemias with BCR-ABL: molecular diagnostic, cytogenetic, and clinical laboratory perspectives. Am J Hematol. 2008;83:901-907.
11. Rowley JD. A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining [letter]. Nature. 1973;243:290-293.
12. Bartram CR, de Klein A, Hagemeijer A, et al. Translocation of c-ab1 oncogene correlates with the presence of a Philadelphia chromosome in chronic myelocytic leukaemia. Nature. 1983;306:277-280.
13. Stoll C, Oberling F. Non-random clonal evolution in 45 cases of chronic myeloid leukemia. Leuk Res. 1979;3:61-66.
14. Melo JV, Kumberova A, van Dijk AG, et al. Investigation on the role of the ATM gene in chronic myeloid leukaemia. Leukemia. 2001;15:1448-1450.
15. Deutsch E, Dugray A, AbdulKarim B, et al. BCR-ABL down-regulates the DNA repair protein DNA-PKcs. Blood. 2001;97:2084-2090.
16. Slupianek A, Schmutte C, Tombline G, et al. BCR/ABL regulates mammalian RecA homologs, resulting in drug resistance. Mol Cell. 2001;8:795-806.
17. Neviani P, Santhanam R, Trotta R, et al. The tumor suppressor PP2A is functionally inactivated in blast crisis CML through the inhibitory activity of the BCR/ABL-regulated SET protein. Cancer Cell. 2005;8:355-368. (Pubitemid 41579831)
18. Druker BJ, Tamura S, Buchdunger E, et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med. 1996;2:561-566. (Pubitemid 26151518)
19. Deininger MW, Goldman JM, Lydon N, et al. The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL-positive cells. Blood. 1997;90:3691-3698. (Pubitemid 27473440)
20. Gambacorti-Passerini C, le Coutre P, Mologni L, et al. Inhibition of the ABL kinase activity blocks the proliferation of BCR/ABL+ leukemic cells and induces apoptosis. Blood Cells Mol Dis. 1997;23:380-394. (Pubitemid 28123720)
21. Heinrich MC, Griffith DJ, Druker BJ, et al. Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor. Blood. 2000;96:925-932.
22. Myllärniemi M, Frösen J, Calderón Ramirez LG, et al. Selective tyrosine kinase inhibitor for the platelet-derived growth factor receptor in vitro inhibits smooth muscle cell proliferation after reinjury of arterial intima in vivo. Cardiovasc Drugs Ther. 1999;13:159-168.
23. O'Brien SG, Guilhot F, Larson RA, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2003;348:994-1004. (Pubitemid 36302244)
24. Druker BJ, Guilhot F, O'Brien SG, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med. 2006;355:2408-2417. (Pubitemid 44903745)
25. Ou J, Vergilio JA, Bagg A. Molecular diagnosis and monitoring in the clinical management of patients with chronic myelogenous leukemia treated with tyrosine kinase inhibitors. Am J Hematol. 2008;83:296-302. (Pubitemid 351458007)
26. Marin D, Kaeda J, Szydlo R, et al. Monitoring patients in complete cytogenetic remission after treatment of CML in chronic phase with imatinib: patterns of residual leukaemia and prognostic factors for cytogenetic relapse. Leukemia. 2005;19:507-512. (Pubitemid 40521152)
27. Hughes TP, Kaeda J, Branford S, et al. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med. 2003;349:1423-1432. (Pubitemid 37211057)
28. Hughes T, Deininger M, Hochhaus A, et al. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood. 2006;108:28-37. (Pubitemid 43990609)
29. Radich JP, Gehly G, Gooley T, et al. Polymerase chain reaction detection of the BCR-ABL fusion transcript after allogeneic marrow transplantation for chronic myeloid leukemia: results and implications in 346 patients. Blood. 1995;85:2632-2638.
30. Mensink E, van de Locht A, Schattenberg A, et al. Quantitation of minimal residual disease in Philadelphia chromosome positive chronic myeloid leukaemia patients using real-time quantitative RT-PCR. Br J Haematol. 1998;102:768-774. (Pubitemid 28387061)
31. Preudhomme C, Revillion F, Merlat A, et al. Detection of BCR-ABL transcripts in chronic myeloid leukemia (CML) using a "real time" quantitative RT-PCR assay. Leukemia. 1999;13:957-964.
32. Lee WI, Kantarjian H, Glassman A, et al. Quantitative measurement of BCR/abl transcripts using real-time polymerase chain reaction. Ann Oncol. 2002;13:781-788. (Pubitemid 34567387)
33. Jones CD, Yeung C, Zehnder JL. Comprehensive validation of a real-time quantitative bcr-abl assay for clinical laboratory use. Am J Clin Pathol. 2003;120:42-48. (Pubitemid 37046368)
34. Kreuzer KA, Lass U, Bohn A, et al. LightCycler technology for the quantitation of bcr/abl fusion transcripts. Cancer Res. 1999;59:3171-3174. (Pubitemid 29316018)
35. Emig M, Saussele S, Wittor H, et al. Accurate and rapid analysis of residual disease in patients with CML using specific fluorescent hybridization probes for real time quantitative RT-PCR. Leukemia. 1999;13:1825-1832. (Pubitemid 29535267)
36. Neumann F, Herold C, Hildebrandt B, et al. Quantitative real-time reverse-transcription polymerase chain reaction for diagnosis of BCR-ABL positive leukemias and molecular monitoring following allogeneic stem cell transplantation. Eur J Haematol. 2003;70:1-10.
37. Stock W, Yu D, Karrison T, et al. Quantitative real-time RT-PCR monitoring of BCR-ABL in chronic myelogenous leukemia shows lack of agreement in blood and bone marrow samples. Int J Oncol. 2006;28:1099-1103.
38. Kreuzer KA, Lass U, Nagel S, et al. Applicability of an absolute quantitative procedure to monitor intraindividual bcr/abl transcript kinetics in clinical samples from chronic myelogenous leukemia patients. Int J Cancer. 2000;86:741-746.
39. Barbany G, Hagberg A, Olsson-Stromberg U, et al. Manifold-assisted reverse transcription-PCR with realtime detection for measurement of the BCR-ABL fusion transcript in chronic myeloid leukemia patients. Clin Chem. 2000;46:913-920.
40. Stentoft J, Pallisgaard N, Kjeldsen E, et al. Kinetics of BCR-ABL fusion transcript levels in chronic myeloid leukemia patients treated with STI571 measured by quantitative real-time polymerase chain reaction. Eur J Haematol. 2001;67:302-308. (Pubitemid 34135443)
41. Martinelli G, Montefusco V, Testoni N, et al. Clinical value of quantitative long-term assessment of bcr-abl chimeric transcript in chronic myelogenous leukemia patients after allogeneic bone marrow transplantation. Haematologica. 2000;85:653-658.
42. Gutierrez MI, Timson G, Siraj AK, et al. Single monochrome real-time RT-PCR assay for identification, quantification, and breakpoint cluster region determination of t(9;22) transcripts. J Mol Diagn. 2005;7:40-47.
43. Bolufer P, Sanz GF, Barragan E, et al. Rapid quantitative detection of BCR-ABL transcripts in chronic myeloid leukemia patients by real-time reverse transcriptase polymerase-chain reaction using fluorescently labeled probes. Haematologica. 2000;85:1248-1254.
44. Branford S, Rudzki Z, Walsh S, et al. Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis. Blood. 2003;102:276-283.
45. Dameshek W. Some speculations on the myeloproliferative disorders. Blood. 1951;6:372.
46. Ruggeri M, Tosetto A, Frezzato M, et al. The rate of progression to polycythemia vera or essential thrombocythemia in patients with erythrocytosis or thrombocytosis. Ann Intern Med. 2003;139:470-475.
47. Thiele J, Kvasnicka HM, Orazi A. Bone marrow histopathology in myeloproliferative disorders: current diagnostic approach. Semin Hematol. 2005;42:184-195. (Pubitemid 41400660)
48. Silverstein MN, Gomes MR, ReMine WH, et al. Agnogenic myeloid metaplasia: natural history and treatment. Arch Intern Med. 1967;120:546-550.
49. Ward HP, Block MH. The natural history of agnogenic myeloid metaplasia (AMM) and a critical evaluation of its relationship with the myeloproliferative syndrome. Medicine (Baltimore). 1971;50:357-420.
50. Varki A, Lottenberg R, Griffith R, et al. The syndrome of idiopathic myelofibrosis: a clinicopathologic review with emphasis on the prognostic variables predicting survival. Medicine (Baltimore). 1983;62:353-371.
51. Tefferi A. Myelofibrosis with myeloid metaplasia. N Engl J Med. 2000;342:1255-1265.
52. Barosi G. Myelofibrosis with myeloid metaplasia: diagnostic definition and prognostic classification for clinical studies and treatment guidelines. J Clin Oncol. 1999;17:2954-2970.
53. Barosi G, Ambrosetti A, Finelli C, et al. The Italian Consensus Conference on Diagnostic Criteria for Myelofibrosis with Myeloid Metaplasia. Br J Haematol. 1999;104:730-737.
54. Thiele J, Kvasnicka HM, Diehl V, et al. Clinicopathological diagnosis and differential criteria of thrombocythemias in various myeloproliferative disorders by histopathology, histochemistry and immunostaining from bone marrow biopsies. Leuk Lymphoma. 1999;33:207-218.
55. Thiele J, Kvasnicka HM, Zankovich R, et al. Clinical and morphological criteria for the diagnosis of prefibrotic idiopathic (primary) myelofibrosis. Ann Hematol. 2001;80:160-165.
56. Thiele J, Kvasnicka HM, Werden C, et al. Idiopathic primary osteo-myelofibrosis: a clinico-pathological study on 208 patients with special emphasis on evolution of disease features, differentiation from essential thrombocythemia and variables of prognostic impact. Leuk Lymphoma. 1996;22:303-317.
57. Tefferi A, Murphy S. Current opinion in essential thrombocythemia: pathogenesis, diagnosis, and management. Blood Rev. 2001;15:121-131. (Pubitemid 32999197)
58. Michiels JJ, Budde U, van der Planken M, et al. Acquired von Willebrand syndromes: clinical features, aetiology, pathophysiology, classification and management. Best Pract Res Clin Haematol. 2001;14:401-436.
59. Iland HJ, Laszlo J, Peterson P, et al. Essential thrombocythemia: clinical and laboratory characteristics at presentation. Trans Assoc Am Physicians. 1983;96:165-174.
60. Gruppo Italiano Studio Policitemia. Polycythemia vera: the natural history of 1213 patients followed for 20 years. Ann Intern Med. 1995;123:656-664.
61. Berk PD, Goldberg JD, Silverstein MN, et al. Increased incidence of acute leukemia in polycythemia vera associated with chlorambucil therapy. N Engl J Med. 1981;304:441-447.
62. Gangat N, Strand J, Li CY, et al. Leucocytosis in polycythaemia vera predicts both inferior survival and leukaemic transformation. Br J Haematol. 2007;138:354-358. (Pubitemid 47035399)
63. Gangat N, Wolanskyj AP, McClure RF, et al. Risk stratification for survival and leukemic transformation in essential thrombocythemia: a single institutional study of 605 patients. Leukemia. 2007;21:270-276. (Pubitemid 46158119)
64. Baxter EJ, Scott LM, Campbell PJ, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet. 2005;365:1054-1061. (Pubitemid 40386783)
65. James C, Ugo V, Le Couedic JP, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature. 2005;434:1144-1148. (Pubitemid 40663494)
66. Kralovics R, Passamonti F, Buser AS, et al. A gain-offunction mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 2005;352:1779-1790. (Pubitemid 40570926)
67. Levine RL, Wadleigh M, Cools J, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell. 2005;7:387-397. (Pubitemid 40544655)
68. Scott LM, Campbell PJ, Baxter EJ, et al. The V617F JAK2 mutation is uncommon in cancers and in myeloid malignancies other than the classic myeloproliferative disorders [letter]. Blood. 2005;106:2920-2921.
69. Jelinek J, Oki Y, Gharibyan V, et al. JAK2 mutation 1849G>T is rare in acute leukemias but can be found in CMML, Philadelphia chromosome-negative CML, and megakaryocytic leukemia. Blood. 2005;106:3370-3373. (Pubitemid 41609167)
70. Tefferi A, Lasho TL, Schwager SM, et al. The JAK2(V617F) tyrosine kinase mutation in myelofibrosis with myeloid metaplasia: lineage specificity and clinical correlates. Br J Haematol. 2005;131:320-328. (Pubitemid 43899664)
71. Campbell PJ, Griesshammer M, Dohner K, et al. V617F mutation in JAK2 is associated with poorer survival in idiopathic myelofibrosis. Blood. 2006;107:2098-2100. (Pubitemid 43289395)
72. Vannucchi AM, Antonioli E, Guglielmelli P, et al. Prospective identification of high-risk polycythemia vera patients based on JAK2(V617F) allele burden. Leukemia. 2007;21:1952-1959. (Pubitemid 47299969)
73. Kittur J, Knudson RA, Lasho TL, et al. Clinical correlates of JAK2V617F allele burden in essential thrombocythemia. Cancer. 2007;109:2279-2284. (Pubitemid 46801558)
74. Cheung B, Radia D, Pantelidis P, et al. The presence of the JAK2 V617F mutation is associated with a higher haemoglobin and increased risk of thrombosis in essential thrombocythaemia [letter]. Br J Haematol. 2006;132:244-245. (Pubitemid 43381559)
75. Barosi G, Bergamaschi G, Marchetti M, et al. JAK2 V617F mutational status predicts progression to large splenomegaly and leukemic transformation in primary myelofibrosis. Blood. 2007;110:4030-4036. (Pubitemid 350248459)
76. Ihle JN, Gilliland DG. JAK2: normal function and role in hematopoietic disorders. Curr Opin Genet Dev. 2007;17:8-14.
77. Delhommeau F, Dupont S, Tonetti C, et al. Evidence that the JAK2 G1849T (V617F) mutation occurs in a lymphomyeloid progenitor in polycythemia vera and idiopathic myelofibrosis. Blood. 2007;109:71-77. (Pubitemid 46053046)
78. Jamieson CH, Gotlib J, Durocher JA, et al. The JAK2 V617F mutation occurs in hematopoietic stem cells in polycythemia vera and predisposes toward erythroid differentiation. Proc Natl Acad Sci U S A. 2006;103:6224-6229.
79. Khwaja A. The role of Janus kinases in haemopoiesis and haematological malignancy. Br J Haematol. 2006;134:366-384. (Pubitemid 44079550)
80. Kralovics R, Teo S-S, Li S, et al. Acquisition of the V617F mutation of JAK2 is a late genetic event in a subset of patients with myeloproliferative disorders. Blood. 2006;108:1377-1380. (Pubitemid 44232040)
81. Nussenzveig RH, Swierczek SI, Jelinek J, et al. Polycythemia vera is not initiated by JAK2V617F mutation. Exp Hematol. 2007;35:32-38. (Pubitemid 46014382)
82. Landgren O, Goldin LR, Kristinsson SY, et al. Increased risks of polycythemia vera, essential thrombocythemia, and myelofibrosis among 24,577 first-degree relatives of 11,039 patients with myeloproliferative neoplasms in Sweden. Blood. 2008;112:2199-2204.
83. Bellanne-Chantelot C, Chaumarel I, Labopin M, et al. Genetic and clinical implications of the Val617Phe JAK2 mutation in 72 families with myeloproliferative disorders. Blood. 2006;108:346-352. (Pubitemid 43990648)
84. Rumi E, Passamonti F, Pietra D, et al. JAK2 (V617F) as an acquired somatic mutation and a secondary genetic event associated with disease progression in familial myeloproliferative disorders. Cancer. 2006;107:2206-2211.
85. Kilpivaara O, Levine RL. JAK2 and MPL mutations in myeloproliferative neoplasms: discovery and science. Leukemia. 2008;22:1813-1817.
86. Theocharides A, Boissinot M, Girodon F, et al. Leukemic blasts in transformed JAK2-V617F-positive myeloproliferative disorders are frequently negative for the JAK2-V617F mutation. Blood. 2007;110:375-379.
87. Campbell PJ, Baxter EJ, Beer PA, et al. Mutation of JAK2 in the myeloproliferative disorders: timing, clonality studies, cytogenetic associations, and role in leukemic transformation. Blood. 2006;108:3548-3555.
88. Tefferi A, Pardanani A, Lim KH, et al. TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis. Leukemia. 2009;23:905-911.
89. Jankowska AM, Szpurka H, Tiu RV, et al. Loss of heterozygosity 4q24 and TET2 mutations associated with myelodysplastic/myeloproliferative neoplasms. Blood. 2009;113:6403-6410.
90. Delhommeau F, Dupont S, Della Valle V, et al. Mutation in TET2 in myeloid cancers. N Engl J Med. 2009;360:2289-2301.
91. Larsen TS, Pallisgaard N, Moller MB, et al. The JAK2 V617F allele burden in essential thrombocythemia, polycythemia vera and primary myelofibrosis: impact on disease phenotype. Eur J Haematol. 2007;79:508-515.
92. Tiedt R, Hao-Shen H, Sobas MA, et al. Ratio of mutant JAK2-V617F to wild-type Jak2 determines the MPD phenotypes in transgenic mice. Blood. 2008;111:3931-3940.
93. Tefferi A, Strand JJ, Lasho TL, et al. Bone marrow JAK2V617F allele burden and clinical correlates in polycythemia vera. Leukemia. 2007;21:2074-2075. (Pubitemid 47299994)
94. Pardanani A, Fridley BL, Lasho TL, et al. Host genetic variation contributes to phenotypic diversity in myeloproliferative disorders. Blood. 2008;111:2785-2789.
95. McClure R, Mai M, Lasho T. Validation of two clinically useful assays for evaluation of JAK2 V617F mutation in chronic myeloproliferative disorders. Leukemia. 2006;20:168-171.
96. Murugesan G, Aboudola S, Szpurka H, et al. Identification of the JAK2 V617F mutation in chronic myeloproliferative disorders using FRET probes and melting curve analysis. Am J Clin Pathol. 2006;125:625-633.
97. Olsen RJ, Tang Z, Farkas DH, et al. Detection of the JAK2(V617F) mutation in myeloproliferative disorders by melting curve analysis using the LightCycler system. Arch Pathol Lab Med. 2006;130:997-1003.
98. Reading NS, Lim MS, Elenitoba-Johnson KS. Detection of acquired Janus kinase 2 V617F mutation in myeloproliferative disorders by fluorescence melting curve analysis. Mol Diagn Ther. 2006;10:311-317.
99. Frantz C, Sekora DM, Henley DC, et al. Comparative evaluation of three JAK2V617F mutation detection methods. Am J Clin Pathol. 2007;128:865-874.
100. Larsen TS, Pallisgaard N, Moller MB, et al. Quantitative assessment of the JAK2 V617F allele burden: equivalent levels in peripheral blood and bone marrow [letter]. Leukemia. 2008;22:194-195.
101. Bock O, Busche G, Koop C, et al. Detection of the single hotspot mutation in the JH2 pseudokinase domain of Janus kinase 2 in bone marrow trephine biopsies derived from chronic myeloproliferative disorders. J Mol Diagn. 2006;8:170-177.
102. Bousquet M, Le Guellec S, Quelen C, et al. Frequent detection of the JAK2 V617F mutation in bone marrow core biopsy specimens from chronic myeloproliferative disorders using the TaqMan polymerase chain reaction single nucleotide polymorphism genotyping assay: a retrospective study with pathologic correlations. Hum Pathol. 2006;37:1458-1464.
103. Horn T, Kremer M, Dechow T, et al. Detection of the activating JAK2 V617F mutation in paraffin-embedded trephine bone marrow biopsies of patients with chronic myeloproliferative diseases. J Mol Diagn. 2006;8:299-304.
104. Aboudola S, Murugesan G, Szpurka H, et al. Bone marrow phospho-STAT5 expression in non-CML chronic myeloproliferative disorders correlates with JAK2 V617F mutation and provides evidence of in vivo JAK2 activation. Am J Surg Pathol. 2007;31:233-239.
105. Sidon P, El Housni H, Dessars B, et al. The JAK2V617F mutation is detectable at very low level in peripheral blood of healthy donors [letter]. Leukemia. 2006;20:1622.
106. Scott LM, Tong W, Levine RL, et al. JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. N Engl J Med. 2007;356:459-468.
107. Royer Y, Staerk J, Costuleanu M, et al. Janus kinases affect thrombopoietin receptor cell surface localization and stability. J Biol Chem. 2005;280:27251-27261.
108. Pardanani AD, Levine RL, Lasho T, et al. MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. Blood. 2006;108:3472-3476.
109. Pikman Y, Lee BH, Mercher T, et al. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med. 2006;3:e270. doi:10.1371/journal. pmed.0030270.
110. Chaligne R, Tonetti C, Besancenot R, et al. New mutations of MPL in primitive myelofibrosis: only the MPL W515 mutations promote a G1/S-phase transition. Leukemia. 2008;22:1557-1566.
111. Beer PA, Campbell PJ, Scott LM, et al. MPL mutations in myeloproliferative disorders: analysis of the PT-1 cohort. Blood. 2008;112:141-149.
112. Pardanani A. JAK2 inhibitor therapy in myeloproliferative disorders: rationale, preclinical studies and ongoing clinical trials. Leukemia. 2008;22:23-30.
113. Pardanani A, Hood J, Lasho T, et al. TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations. Leukemia. 2007;21:1658-1668.
114. Russell SM, Tayebi N, Nakajima H, et al. Mutation of JAK3 in a patient with SCID: essential role of JAK3 in lymphoid development. Science. 1995;270:797-800.
115. Lasho TL, Tefferi A, Hood JD, et al. TG101348, a JAK2-selective antagonist, inhibits primary hematopoietic cells derived from myeloproliferative disorder patients with JAK2V617F, MPLW515K or JAK2 exon 12 mutations as well as mutation negative patients [letter]. Leukemia. 2008;22:1790-1792.
116. Cools J, DeAngelo DJ, Gotlib J, et al. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med. 2003;348:1201-1214.
117. Baxter EJ, Hochhaus A, Bolufer P, et al. The t(4;22) (q12;q11) in atypical chronic myeloid leukaemia fuses BCR to PDGFRA. Hum Mol Genet. 2002;11:1391-1397.
118. Curtis CE, Grand FH, Waghorn K, et al. A novel ETV6-PDGFRB fusion transcript missed by standard screening in a patient with an imatinib responsive chronic myeloproliferative disease. Leukemia. 2007;21:1839-1841.
119. Metzgeroth G, Walz C, Score J, et al. Recurrent finding of the FIP1L1-PDGFRA fusion gene in eosinophilia-associated acute myeloid leukemia and lymphoblastic T-cell lymphoma. Leukemia. 2007;21:1183-1188.
120. Golub TR, Barker GF, Lovett M, et al. Fusion of PDGF receptor beta to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation. Cell. 1994;77:307-316.
121. Kulkarni S, Heath C, Parker S, et al. Fusion of H4/D10S170 to the platelet-derived growth factor receptor beta in BCR-ABL-negative myeloproliferative disorders with a t(5;10)(q33;q21). Cancer Res. 2000;60:3592-3598.
122. Walz C, Metzgeroth G, Haferlach C, et al. Characterization of three new imatinib-responsive fusion genes in chronic myeloproliferative disorders generated by disruption of the platelet-derived growth factor receptor beta gene. Haematologica. 2007;92:163-169.
123. Inhorn RC, Aster JC, Roach SA, et al. A syndrome of lymphoblastic lymphoma, eosinophilia, and myeloid hyperplasia/malignancy associated with t(8;13)(p11;q11): description of a distinctive clinicopathologic entity. Blood. 1995;85:1881-1887.
124. Macdonald D, Reiter A, Cross NC. The 8p11 myeloproliferative syndrome: a distinct clinical entity caused by constitutive activation of FGFR1. Acta Haematol. 2002;107:101-107.
125. Lierman E, Folens C, Stover EH, et al. Sorafenib is a potent inhibitor of FIP1L1-PDGFRá and the imatinib-resistant FIP1L1-PDGFRá T674I mutant. Blood. 2006;108:1374-1376. (Pubitemid 44232039)
126. Lierman E, Michaux L, Beullens E, et al. FIP1L1-PDGFRalpha D842V, a novel panresistant mutant, emerging after treatment of FIP1L1-PDGFRalpha T674I eosinophilic leukemia with single agent sorafenib. Leukemia. 2009;23:845-851.
127. Cross NC, Reiter A. Fibroblast growth factor receptor and platelet-derived growth factor receptor abnormalities in eosinophilic myeloproliferative disorders. Acta Haematol. 2008;119:199-206.
128. Tefferi A, Pardanani A. Systemic mastocytosis: current concepts and treatment advances. Curr Hematol Rep. 2004;3:197-202.
129. Sundstrom M, Vliagoftis H, Karlberg P, et al. Functional and phenotypic studies of two variants of a human mast cell line with a distinct set of mutations in the c-kit proto-oncogene. Immunology. 2003;108:89-97. (Pubitemid 36110869)
130. Furitsu T, Tsujimura T, Tono T, et al. Identification of mutations in the coding sequence of the proto-oncogene c-kit in a human mast cell leukemia cell line causing ligandindependent activation of c-kit product. J Clin Invest. 1993;92:1736-1744. (Pubitemid 23304537)
131. Tefferi A, Verstovsek S, Pardanani A. How we diagnose and treat WHO-defined systemic mastocytosis in adults. Haematologica. 2008;93:6-9.
132. Horny HP, Valent P. Diagnosis of mastocytosis: general histopathological aspects, morphological criteria, and immunohistochemical findings. Leuk Res. 2001;25:543-551.
133. Longley BJ Jr, Metcalfe DD, Tharp M, et al. Activating and dominant inactivating c-KIT catalytic domain mutations in distinct clinical forms of human mastocytosis. Proc Natl Acad Sci U S A. 1999;96:1609-1614.
134. Akin C, Kirshenbaum AS, Semere T, et al. Analysis of the surface expression of c-kit and occurrence of the c-kit Asp816Val activating mutation in T cells, B cells, and myelomonocytic cells in patients with mastocytosis. Exp Hematol. 2000;28:140-147.
135. Kahler C, Didlaukat S, Feller AC, et al. Sensitive and reliable detection of Kit point mutation Asp 816 to Val in pathological material. Diagn Pathol. 2007;2:37. doi:10.1186/1746-1596-2-37.
136. Schumacher JA, Elenitoba-Johnson KS, Lim MS. Detection of the c-kit D816V mutation in systemic mastocytosis by allele-specific PCR. J Clin Pathol. 2008;61:109-114.
137. Tefferi A, Levine RL, Lim KH, et al. Frequent TET2 mutations in systemic mastocytosis: clinical, KITD816V and FIP1L1-PDGFRA correlates. Leukemia. 2009;23:900-904.
138. Taniguchi M, Nishida T, Hirota S, et al. Effect of c-kit mutation on prognosis of gastrointestinal stromal tumors. Cancer Res. 1999;59:4297-4300.
139. Hirota S, Isozaki K, Moriyama Y, et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science. 1998;279:577-580. (Pubitemid 28067289)
140. Ma Y, Zeng S, Metcalfe DD, et al. The c-KIT mutation causing human mastocytosis is resistant to STI571 and other KIT kinase inhibitors: kinases with enzymatic site mutations show different inhibitor sensitivity profiles than wild-type kinases and those with regulatory-type mutations. Blood. 2002;99:1741-1744.
141. Frost MJ, Ferrao PT, Hughes TP, et al. Juxtamembrane mutant V560GKit is more sensitive to imatinib (STI571) compared with wild-type c-kit whereas the kinase domain mutant D816VKit is resistant. Mol Cancer Ther. 2002;1:1115-1124.
142. Quintas-Cardama A, Aribi A, Cortes J, et al. Novel approaches in the treatment of systemic mastocytosis. Cancer. 2006;107:1429-1439.
143. Reilly JT. Chronic neutrophilic leukaemia: a distinct clinical entity? Br J Haematol. 2002;116:10-18.
144. Verstovsek S, Lin H, Kantarjian H, et al. Neutrophilicchronic myeloid leukemia: low levels of p230 BCR/ABL mRNA and undetectable BCR/ABL protein may predict an indolent course. Cancer. 2002;94:2416-2425.